|By JCN Newswire||
|July 24, 2014 02:15 AM EDT||
Tokyo, July 24, 2014 - (JCN Newswire) - Mitsubishi Heavy Industries, Ltd. (MHI) has received an order for the "Vero4DT," a radiation therapy system featuring dynamic tracking irradiation capability - marketed as the "MHI-TM2000 Linear Accelerator" - for the Hiroshima High-precision Radiotherapy Center, a cutting-edge cancer radiotherapy facility slated to open in Hiroshima Prefecture in Autumn 2015. The order is the first from Hiroshima Prefecture, where the Vero4DRT is manufactured, and with it cumulative orders to date now exceed 30 units. Therapy using the new system will commence simultaneous to the opening of the new facility.
The Hiroshima High-precision Radiotherapy Center is currently under construction in the redevelopment zone (Futabanosato) at the north entrance to the Japan Railway's (JR) Hiroshima Station, a project overseen by the prefectural government. The implementing body is the Hiroshima Prefectural Medical Association, and the Center will be jointly operated by seven entities: the Hiroshima Prefectural Medical Association, Hiroshima City, Hiroshima Prefecture and four key hospitals, i.e. Hiroshima University Hospital, Hiroshima Prefectural Hospital, Hiroshima City Hiroshima Citizens Hospital, and Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital. The facility is eagerly expected to serve the Hiroshima region as a cutting-edge medical center specializing in advanced radiotherapy.
The Vero4DRT system features a dynamic tracking function that tracks a respiratorily moving carcinomatous lesion in real time, enabling continuous irradiation of the targeted lesion with pinpoint accuracy. The system also incorporates Intensity-Modulated Radiation Therapy (IMRT), an innovative therapy method whereby dose intensity distribution at the irradiation target is modulated and irradiation is performed from multiple directions, enabling the formation of a high-dose area corresponding precisely to the complex shape of the carcinomatous lesion and reduction in the dose irradiated to healthy cells. In these ways the Vero4DRT is capable of providing today's most advanced high-precision radiotherapy corresponding perfectly to the conceptual aims behind creation of the new Center.
In developing the Vero4DRT system, MHI was supported by the New Energy and Industrial Technology Development Organization (NEDO). Marketing got under way in January 2008 following acquisition of pharmaceutical approval of the system. The Vero4DRT, which is manufactured at MHI's Hiroshima Machinery Works, adopts a new type of accelerating tube, the first in the world applied to medical use, jointly developed with the High Energy Accelerator Research Organization (KEK) and manufactured at the company's Mihara Machinery Works; it enables free machine movement by compactly containing the high-quality therapeutic radiation source. The unit is also equipped with a system that enables simple, convenient irradiation focusing. Together these innovative features enable swift and accurate radiotherapy while easing the burden on both the patient and the attending medical staff.
Today, as expectations are held for expanding adoption of effective cancer therapies that are gentle on patients, facilities that conduct radiotherapy - a therapy that eliminates the need for invasive surgery - are projected to increase. In order to respond, even in a small way, to these social needs, going forward MHI will work aggressively to expand sales of its highly innovative Vero4DRT system.
About Mitsubishi Heavy Industries
Since its foundation in 1884, Mitsubishi Heavy Industries (MHI) has sought pioneering new monodzukuri (manufacturing) techniques, building the foundations for the development of the entire industry. Today, with environmental and energy issues to the fore, MHI provides people around the world with eco-friendly products, and contributes to society through its involvement in global infrastructure projects and other business activities. For more information, please visit the MHI website at www.mhi.co.jp.
Source: Mitsubishi Heavy Industries
Mitsubishi Heavy Industries Hideo Ikuno [email protected] +81-3-6716-5277
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Oct. 23, 2016 08:15 AM EDT Reads: 4,336
Oct. 23, 2016 08:00 AM EDT Reads: 8,315
Oct. 23, 2016 08:00 AM EDT Reads: 5,674
Oct. 23, 2016 07:00 AM EDT Reads: 4,094
Oct. 23, 2016 06:30 AM EDT Reads: 4,735
Oct. 23, 2016 06:15 AM EDT Reads: 16,347
Oct. 23, 2016 06:00 AM EDT Reads: 683
Oct. 23, 2016 05:30 AM EDT Reads: 3,920
Oct. 23, 2016 05:15 AM EDT Reads: 1,834
Oct. 23, 2016 04:00 AM EDT Reads: 3,925
Oct. 23, 2016 03:45 AM EDT Reads: 1,694
Oct. 23, 2016 03:45 AM EDT Reads: 3,305
Oct. 23, 2016 03:30 AM EDT Reads: 2,952
Oct. 23, 2016 03:30 AM EDT Reads: 1,442
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
Oct. 23, 2016 03:00 AM EDT Reads: 1,272